Tofacitinib

Tofacitinib | JAK (Janus Kinase Pathway) Inhibitor Tofacitinib - pharmacology, mechanism of action.

Animated biology With arpan

ACR 2020 | Atul Deodhar discusses a phase 3 trial of tofacitinib in ankylosing spondylitis

Medicine Matters rheumatology

Efficacy and safety of tofacitinib following inadequate response to conventional antirheumatic drugs

Annals of the Rheumatic Diseases

Tofacitinib, an oral Janus kinase inhibitor

Annals of the Rheumatic Diseases

Expert commentary: Safety and efficacy of tofacitinib in JIA | Sangeeta Sule

Medicine Matters rheumatology

Flu and Tofacitinib: Dr. Kathryn Dao

JAK (Janus Kinase Pathway) Inhibitor Tofacitinib - pharmacology, mechanism of action, side effects

Armando Hasudungan

Tofacitinib as Monotherapy Following MTX Withdrawal in PsA: Dr. Eric Ruderman

Tofacitinib and RA-ILD

5 Questions on Tofacitinib/PsA FDA Hearing - Dr. Jack Cush

Tofacitinib: how fast does it work? How early can you expect pain relief?

Dr Shashank Akerkar

Dr. Cassie Calabrese - Zoster Vaccination on Tofacitinib

ORAL Surveillance Tofacitinib Safety Panel

TB and opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Jak Inhibitors: Safety of Tofacitinib - Alexei Grom (on behalf of Hermine Brunner)

ACR 2020 | Marina Magrey comments on a phase 3 trial of tofacitinib in ankylosing spondylitis

Medicine Matters rheumatology

Tofacitinib (Xeljanz) - IBD treatments explained by the experts

Rheumat TV : Tofacitinib: Friend or Foe ? by Dr Abhishek Zanwar

Ortho TV : Orthopaedic Video Channel

Ankylosing spondylitis: How long is the course of biologics/ Tofacitinib?

Dr Shashank Akerkar

Tofacitinib in dermatology

Dermacoaching by Dr. Niharika Jha